BioCryst Pharmaceuticals (NASDAQ:BCRX) Hits New 12-Month High - Still a Buy?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $11.15 and last traded at $10.93, with a volume of 581433 shares traded. The stock had previously closed at $10.75.

Analyst Ratings Changes

Several brokerages recently issued reports on BCRX. Cantor Fitzgerald began coverage on BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They set an "overweight" rating and a $20.00 target price for the company. Needham & Company LLC raised their target price on BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $13.00 target price (up from $11.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Wall Street Zen raised BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 22nd. Finally, Wedbush initiated coverage on BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an "outperform" rating and a $15.00 target price for the company. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $16.56.

BioCryst Pharmaceuticals Trading Up 4.3%

The company has a 50-day moving average price of $8.79 and a two-hundred day moving average price of $8.20. The stock has a market capitalization of $2.34 billion, a P/E ratio of -18.34 and a beta of 1.08.

Institutional Trading of BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Allianz Asset Management GmbH increased its position in BioCryst Pharmaceuticals by 9.6% in the 1st quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company's stock valued at $103,000 after buying an additional 1,200 shares in the last quarter. Xponance Inc. increased its position in BioCryst Pharmaceuticals by 9.1% in the 4th quarter. Xponance Inc. now owns 14,896 shares of the biotechnology company's stock valued at $112,000 after buying an additional 1,242 shares in the last quarter. Royal Bank of Canada increased its position in BioCryst Pharmaceuticals by 2.4% in the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company's stock valued at $476,000 after buying an additional 1,458 shares in the last quarter. Sei Investments Co. increased its position in BioCryst Pharmaceuticals by 2.8% in the 4th quarter. Sei Investments Co. now owns 57,190 shares of the biotechnology company's stock valued at $430,000 after buying an additional 1,537 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in BioCryst Pharmaceuticals by 5.2% in the 1st quarter. SG Americas Securities LLC now owns 43,496 shares of the biotechnology company's stock valued at $326,000 after buying an additional 2,146 shares in the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.